<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-id journal-id-type="publisher-id">PJMS</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26870122</article-id><article-id pub-id-type="pmc">4744307</article-id><article-id pub-id-type="publisher-id">PJMS-31-1490</article-id><article-id pub-id-type="doi">10.12669/pjms.316.7955</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of embolic agents with different particle sizes on interventional treatment of uterine fibroids</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xigong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhengfu</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Jirong</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Weizhong</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Xigong Wang, Department of Cancer Intervention, Qingdao Central Hospital, Qingdao 266042, China</aff><aff id="aff2"><label>2</label>Zhengfu Zhang, Department of Radiology, Qingdao Central Hospital, Qingdao 266042, China</aff><aff id="aff3"><label>3</label>Jirong Pan, Department of B Ultrasonic Room, Qingdao Municipal Hospital, Qingdao 266071, China</aff><aff id="aff4"><label>4</label>Weizhong Zhang, Department of Interventional Radiology, Qingdao Municipal Hospital, Qingdao 266071, China</aff><author-notes><corresp id="cor1">
Correspondence: Weizhong Zhang, Dept. of Interventional Radiology, Qingdao Municipal Hospital, No. 5 Donghaizhong Road, Qingdao 266071, China. E-mail: <email xlink:href="zhangwzdir@163.com">zhangwzdir@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2015</year></pub-date><volume>31</volume><issue>6</issue><fpage>1490</fpage><lpage>1495</lpage><history><date date-type="received"><day>14</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>15</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To compare the effects of embolic agents with different particle sizes on interventional treatment of uterine fibroids (UFs).</p></sec><sec id="st2"><title>Methods:</title><p>One-hundred and thirty patients with UFs were divided into a treatment group and a control group (n=65) by random draw. All patients were treated by uterine artery embolization, with the treatment group using 200 &#x003bc;m polyvinyl alcohol (PVA) particles and the control group using 500 &#x003bc;m PVA particles.</p></sec><sec id="st3"><title>Results:</title><p>The success rate of embolization was 100%. After intervention, the treatment group was significantly less prone to complications such as lower abdominal pain, fever, nausea, vomiting and bleeding than the control group (P&#x0003c;0.05). The follicle-stimulating hormone levels of both groups were similar before and after intervention, and there were also no significant inter-group differences. The uterine and UF volumes of both groups significantly decreased six months after intervention (P&#x0003c;0.05), and those of the treatment group were significantly lower (P&#x0003c;0.05). The two groups had similar physical function, role-physical, bodily pain and general health scores before intervention, but the treatment group scored significantly higher than the control group did six months after intervention (P&#x0003c;0.05).</p></sec><sec id="st4"><title>Conclusion:</title><p>Interventional embolization can well treat UFs, without apparently affecting ovarian functions. Small-sized PVA particles can improve the quality of life by shrinking the uterus and UFs as well as by reducing the risks of complications.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Uterine fibroid</kwd><kwd>Embolic agent</kwd><kwd>Particle size</kwd><kwd>Quality of life</kwd><kwd>Ovarian function</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Uterine fibroid (UF), which is a benign tumor composed by proliferated uterine smooth muscle tissues and various numbers of fibrous connective tissues, is the most common female pelvic disease threatening women of childbearing age.<xref rid="ref1" ref-type="bibr">1</xref> Clinically manifested as abnormal uterine bleeding, pelvic pressure, frequent urination, dysuria, urinary retention, pain and loss of fertility, UFs severely endanger female physical and psychological healths.<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref3" ref-type="bibr">3</xref> The pathogenesis of UFs remains unclear hitherto, which has most been associated with the changes of extracellular matrix, environmental factors, progesterone, growth factors, gene mutation and estrogen as sex hormone-dependent tumors.<xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref5" ref-type="bibr">5</xref> UFs have been traditionally treated by panhysterectomy, myomectomy and hormone therapy, but surgeries negatively affect patients both physically and psychologically. Besides, hormone therapy, which mainly employs progesterone and gonadotropin-releasing hormone, easily leads to recurrence and even osteoporosis.<xref rid="ref2" ref-type="bibr">2</xref></p><p>Recently, minimally invasive uterine artery embolization (UAE) has been widely applied in clinical practice due to minor traumas, high tolerance, scare complications and satisfactory therapeutic effects. In addition, the uterus can be retained for the patients who have reproductive demands. In general, eligible embolic agents only mildly or do not affect normal tissues and organs, and do not result in obvious complications such as pain.<xref rid="ref6" ref-type="bibr">6</xref> The aim of UAE is to block the blood supply of UFs before capillaries by using microparticles, allowing ischemic necrosis and atrophy.<xref rid="ref7" ref-type="bibr">7</xref></p><p>Being highly stable, biocompatible and non-toxic, polyvinyl alcohol (PVA) particles have permanent embolizing effects in human body and do not enter distal radial arteries or small spiral arteries, thus maintaining myometrial vessels unobstructed.<xref rid="ref8" ref-type="bibr">8</xref> Nowadays, 500 &#x003bc;m PVA particles are used most often, and 200 &#x003bc;m ones have also been applicable.<xref rid="ref9" ref-type="bibr">9</xref> In this study, the effects of embolic agents with different particle sizes on interventional treatment of UFs were compared, aiming to provide evidence for future use.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>Subjects</title><p>One-hundred and thirty patients with UFs, who were treated in our hospital from July 2011 to February 2014, were selected. All of them were diagnosed by clinical symptoms, gynecological examination and imaging data (B-scan ultrasonography and MRI, etc.).</p></sec><sec id="sec2-2"><title>Inclusion criteria</title><p>Women in the child-bearing period who had given birth, with increased menstruation as the main symptom; clinically manifested as menstrual changes, pelvic pressure and dysmenorrhea; with over 6 months of follow-up data; unwilling to receive surgeries or refused to do so owing to future reproductive demands; with written consent form; diagnoses as submucosal or intramural fibroids by imaging, without other uterine pathological changes.</p></sec><sec id="sec2-3"><title>Exclusion criteria</title><p>With large angiographic contraindications; with pedunculated fibroids and enlarged uteri while being over 25-week pregnant; with severe arteriosclerosis and the elderly. The patients were divided into a treatment group and a control group (n=65) by random method, and the two groups had similar age, disease course, uterine volume, UF volume, UF status and body mass index before intervention (P&#x0003e;0.05) (<xref ref-type="table" rid="T1">Table-I</xref>).</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Baseline data.</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Index</th><th align="center" rowspan="1" colspan="1">Treatment group (n=65)</th><th align="center" rowspan="1" colspan="1">Control group (n=65)</th><th align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> or t</th><th align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">41.83&#x000b1;4.92</td><td align="center" rowspan="1" colspan="1">41.78&#x000b1;5.00</td><td align="center" rowspan="1" colspan="1">0.153</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Disease course (year)</td><td align="center" rowspan="1" colspan="1">3.76&#x000b1;1.08</td><td align="center" rowspan="1" colspan="1">3.72&#x000b1;1.00</td><td align="center" rowspan="1" colspan="1">0.221</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Uterine volume (cm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">290.78&#x000b1;14.88</td><td align="center" rowspan="1" colspan="1">291.73&#x000b1;16.33</td><td align="center" rowspan="1" colspan="1">0.045</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">UF volume (cm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">114.87&#x000b1;13.00</td><td align="center" rowspan="1" colspan="1">116.37&#x000b1;12.63</td><td align="center" rowspan="1" colspan="1">0.183</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">22.38&#x000b1;2.61</td><td align="center" rowspan="1" colspan="1">22.41&#x000b1;3.09</td><td align="center" rowspan="1" colspan="1">0.089</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-4"><title>Treatment methods</title><p>All patients were subjected to UAE and digital subtraction angiography by using GE 64-layer spiral CT scanner and Phillips V-5000 X-ray system. Non-ionic contrast agent iopamidol was used as the contrast agent, and 200 &#x003bc;m and 500 &#x003bc;m PVA particles (Cook) were used as the embolic agents. The treatment group and the control group were treated with 200 &#x003bc;m and 500 &#x003bc;m PVA particles respectively. UAE was conducted within 3-7 days after menstruation. All patients were locally anesthetized by 2% lidocaine, and catheterized through the right femoral artery with the Seldinger technique. Then bilateral internal iliac arteries were horizontally catheterized on the abdominal aortic bifurcation by 5F catheters before DSA, and Cobra catheters were inserted into left and right uterine arteries respectively. Afterwards, DSA was carried out again to display the blood supply characteristics of UFs. Under imaging guidance, PVA particles were thoroughly mixed with contrast agent and slowly injected into UF blood vessels. A total of 40-150 mg embolic agents were used, with the average of 90 mg. After UAE, aortic angiography was performed before removal of the catheters.</p></sec><sec id="sec2-5"><title>Observation indices</title><p>The success rate of UAE was observed, and postoperative complications after intervention, such as abdominal pain, fever, nausea, vomiting and bleeding, were observed. Uterine and UF volumes were measured six months before and after treatment by using color Doppler ultrasound scanner.</p><p>Six months before and after intervention, fasting levels of follicle-stimulating hormone (FSH) were measured to monitor the changes of ovarian function.</p><p>The overall therapeutic effects were evaluated six months after intervention. Marked effective: Significant reduction of menstrual flow, uterine and UF volumes decreased by &#x02265;50%; effective: significant reduction of menstrual flow, uterine and UF volumes decreased by 20%-50%; ineffective: mild or no reduction of menstrual flow, uterine and UF volumes decreased by &#x0003c;20%.</p><p>The quality of life was investigated with SF-36 health survey by telephone or clinical visit six months before and after intervention. The survey involved physical function, role-physical, bodily pain and general health status, and a higher score meant better quality of life.</p></sec><sec id="sec2-6"><title>Statistical analysis</title><p>All data were analyzed by SPSS 17.0. The numerical data were compared by the &#x003c7;<sup>2</sup> test of fourfold or row-column tables. The categorical data were expressed as (mean &#x000b1; standard deviation). Intra- and inter-group comparisons were performed with univariate analysis of variance and t test. P&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-7"><title>Complications</title><p>The success rate of UAE was 100%. After intervention, the treatment group was significantly less prone to complications such as lower abdominal pain, fever, nausea, vomiting and bleeding than the control group (P&#x0003c;0.05) (<xref ref-type="table" rid="T2">Table-II</xref>). All complications were relieved by further treatment, without affecting normal menstrual cycle.</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Complications after intervention (n).</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Case number (n)</th><th align="center" rowspan="1" colspan="1">Lower abdominal pain</th><th align="center" rowspan="1" colspan="1">Fever</th><th align="center" rowspan="1" colspan="1">Nausea and vomiting</th><th align="center" rowspan="1" colspan="1">Bleeding</th><th align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7 (10.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">17 (26.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8.553</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-8"><title>Changes of uterine and UF volumes</title><p>The uterine and UF volumes of both groups significantly decreased six months after intervention (P&#x0003c;0.05), and those of the treatment group were significantly lower (P&#x0003c;0.05) (<xref ref-type="table" rid="T3">Table-III</xref>).</p><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Uterine and UF volumes before and after intervention (cm<sup>3</sup>, x&#x000b1;s).</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="2" valign="top" colspan="1">Group</th><th align="center" rowspan="2" valign="top" colspan="1">Case number (n)</th><th align="center" colspan="2" rowspan="1">Uterine volume</th><th align="center" colspan="2" rowspan="1">UF volume</th></tr><tr><th align="left" rowspan="1" colspan="1">Before</th><th align="left" rowspan="1" colspan="1">Six months before</th><th align="left" rowspan="1" colspan="1">Before</th><th align="left" rowspan="1" colspan="1">Six months before</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">290.78&#x000b1;14.88</td><td align="left" rowspan="1" colspan="1">168.24&#x000b1;12.87<xref ref-type="table-fn" rid="t3f1">*</xref></td><td align="left" rowspan="1" colspan="1">114.87&#x000b1;13.00</td><td align="left" rowspan="1" colspan="1">23.94&#x000b1;9.44<xref ref-type="table-fn" rid="t3f1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">291.73&#x000b1;16.33</td><td align="left" rowspan="1" colspan="1">123.76&#x000b1;13.99<xref ref-type="table-fn" rid="t3f1">*</xref></td><td align="left" rowspan="1" colspan="1">116.37&#x000b1;12.63</td><td align="left" rowspan="1" colspan="1">44.73&#x000b1;10.67<xref ref-type="table-fn" rid="t3f1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.045</td><td align="left" rowspan="1" colspan="1">14.998</td><td align="left" rowspan="1" colspan="1">0.183</td><td align="left" rowspan="1" colspan="1">19.334</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table><table-wrap-foot><fn id="t3f1"><label>*</label><p>Compared with the data before intervention,P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-9"><title>FSH level changes</title><p>The FSH levels of both groups were similar before and after intervention, and there were also no significant inter-group differences (<xref ref-type="table" rid="T4">Table-IV</xref>).</p><table-wrap id="T4" position="float"><label>Table-IV</label><caption><p>FSH level changes before and after intervention (IU/L, x&#x000b1;s).</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Case number (n)</th><th align="left" rowspan="1" colspan="1">Before</th><th align="left" rowspan="1" colspan="1">Six months before</th><th align="left" rowspan="1" colspan="1">t</th><th align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">9.99&#x000b1;4.38</td><td align="left" rowspan="1" colspan="1">10.09&#x000b1;4.33</td><td align="left" rowspan="1" colspan="1">0.453</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">10.10&#x000b1;3.89</td><td align="left" rowspan="1" colspan="1">10.66&#x000b1;5.21</td><td align="left" rowspan="1" colspan="1">0.500</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.145</td><td align="left" rowspan="1" colspan="1">0.398</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec id="sec2-10"><title>Scores of quality of life</title><p>The two groups had similar physical function, role-physical, bodily pain and general health scores before intervention, but the treatment group scored significantly higher than the control group did six months after intervention (P&#x0003c;0.05) (<xref ref-type="table" rid="T5">Table-V</xref>).</p><table-wrap id="T5" position="float"><label>Table-V</label><caption><p>Scores of quality of life.</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Case number (n)</th><th align="left" rowspan="1" colspan="1">Physical function</th><th align="left" rowspan="1" colspan="1">Role-physical</th><th align="left" rowspan="1" colspan="1">Bodily pain</th><th align="left" rowspan="1" colspan="1">General health status</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1"><italic>Before</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Treatment group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">55.38&#x000b1;5.33</td><td align="left" rowspan="1" colspan="1">48.98&#x000b1;6.37</td><td align="left" rowspan="1" colspan="1">56.92&#x000b1;5.09</td><td align="left" rowspan="1" colspan="1">57.11&#x000b1;6.02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">55.37&#x000b1;4.02</td><td align="left" rowspan="1" colspan="1">48.77&#x000b1;6.20</td><td align="left" rowspan="1" colspan="1">57.00&#x000b1;5.22</td><td align="left" rowspan="1" colspan="1">57.28&#x000b1;6.22</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;t</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">0.056</td><td align="left" rowspan="1" colspan="1">0.067</td><td align="left" rowspan="1" colspan="1">0.055</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;P</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" colspan="6" rowspan="1"><italic>After</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Treatment group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">83.47&#x000b1;6.44</td><td align="left" rowspan="1" colspan="1">84.78&#x000b1;7.03</td><td align="left" rowspan="1" colspan="1">84.29&#x000b1;6.00</td><td align="left" rowspan="1" colspan="1">85.92&#x000b1;5.11</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Control group</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">74.93&#x000b1;5.09</td><td align="left" rowspan="1" colspan="1">78.46&#x000b1;6.00</td><td align="left" rowspan="1" colspan="1">75.99&#x000b1;5.30</td><td align="left" rowspan="1" colspan="1">71.63&#x000b1;6.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;t</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.983</td><td align="left" rowspan="1" colspan="1">4.983</td><td align="left" rowspan="1" colspan="1">6.449</td><td align="left" rowspan="1" colspan="1">8.444</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;P</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>As an essential organ of female, the uterus plays a crucial role in formation of menstruation, giving birth, endocrine function, pelvic floor support, ovarian blood supply and hemodynamic maintenance<xref rid="ref10" ref-type="bibr">10</xref> by producing a variety of bioactive substances. Meanwhile, modern women have paid particular attention to the improvement of quality of life, which allows wide application of novel minimally invasive treatment methods that can retain the uterus.<xref rid="ref11" ref-type="bibr">11</xref> UFs are benign tumors comprising proliferated uterine smooth-muscle tissues and fibrous connective tissues. Without apparent symptoms in most cases, UFs are usually accidentally detected during pelvic examination. As UFs progress, the patients begin to suffer from menstrual change, lower abdominal mass, pelvic pressure, increased vaginal discharge, abdominal pain, infertility and secondary anemia, etc. The pathogenesis of UFs remains unclear, which is commonly attributed to hormone dependence because they are mainly found in women with ovarian hyperfunction.<xref rid="ref12" ref-type="bibr">12</xref></p><p>Traditionally, UFs are treated with panhysterectomy to prevent possible relapse and malignant transformation. However, this method is greatly traumatic and destroys the integrity of the pelvic floor, thus probably decreasing the quality of life after intervention and negatively affecting patients psychologically as well.<xref rid="ref13" ref-type="bibr">13</xref> Although subtotal hysterectomy has lower risk and reserves the cervix, malignant transformation may occur. Besides, conservative therapy with hormones requires long-term administration and easily leads to complications. In the meantime, the risk of malignant transformation is raised after stopping drug administration owing to endocrine disorders and rapid growth of UFs.<xref rid="ref14" ref-type="bibr">14</xref></p><p>Anatomically speaking, blood in a normal uterus is mainly supplied by bilateral uterine arteries and occasionally by ovarian arteries, constituting a rich vascular network. Therefore, embolizing the end of uterine arteries can render UF tissues to undergo ischemic necrosis and atrophy, whereas the normal myometrium that has abundant blood vessels does not undergo massive necrosis, thus maintaining normal uterine tissues intact and physical functions normal.<xref rid="ref15" ref-type="bibr">15</xref> In the meantime, interventional embolization therapy, which does not require laparotomy, is minimally invasive. Clinical symptoms can be alleviated while retaining the physical functions of the uterus and ovary, and this procedure can be repeated upon incomplete treatment or relapse. Moreover, the highly biocompatible, nontoxic PVA particles remain permanently effective in human body.<xref rid="ref16" ref-type="bibr">16</xref> PVA particles, when used, do not enter distal radial arteries or small spiral arteries, which conforms to the vascular anatomical requirements. In this study, the success rate of UAE was as high as 100%.</p><p>Since the diameters of small uterine arteries range from 300 to 1000 &#x003bc;m and those of small arteries dominating the basal layer of the endometrium are from 30 to 300 &#x003bc;m, PVA particles diametered less than 300 &#x003bc;m are commonly selected. In comparison, 200 &#x003bc;m PVA particles can enter deep uterine vessels, thus allowing more effective UAE that evidently shrinks the uterus and UFs as well as improves the prognosis.<xref rid="ref17" ref-type="bibr">17</xref> The uterus and UF volumes of both groups significantly shrank six months after intervention (P&#x0003c;0.05), and those of the treatment group changed significantly more obviously (P&#x0003c;0.05). Though UAE barely induces postoperative complications, lower abdominal pain, fever, nausea, vomiting and bleeding should be treated in time. Moreover, 500 &#x003bc;m particles may lead to more complications because small uterine arteries were diametered less than this and UFs cannot be completely embolized. After intervention, the treatment group had significantly less complications such as lower abdominal pain, fever, nausea, vomiting and bleeding than the control group did (P&#x0003c;0.05). All complications were mitigated by further treatment, without affecting normal menstrual cycle.</p><p>By using 200 &#x000b5;m PVA particles to embolize uterine arteries, Hehenkamp et al.<xref rid="ref18" ref-type="bibr">18</xref> found that the minimum arterial diameter for these particles to remain was 300 &#x000b5;m. As the smallest particles used hitherto, they successfully blocked the vascular network surrounding fibroids for a long time, without affecting normal uterine supply. Aziz et al.<xref rid="ref19" ref-type="bibr">19</xref> performed UAE through uterine arteries by using PVA particles diametered 200 &#x000b5;m and hysterectomy thereafter, and found that these particles were mainly distributed in parauterine and uterine wall surface arteries diametered 1-2 mm (minimum: &#x0003e;300 &#x000b5;m). Pelage et al.<xref rid="ref20" ref-type="bibr">20</xref> embolized UFs by using 500 &#x000b5;m PVA particles, but MRI analysis showed considerable residual blood supply and easy relapse of these UFs. James et al.<xref rid="ref21" ref-type="bibr">21</xref> reported that UFs in 20% of 200 patients who were treated by 500 &#x000b5;m PVA particles for embolization relapsed after one year of follow-up. Besides, these particles exerted obvious therapeutic effects only on UFs with small volumes and rich blood supply.</p><p>UFs depend on hormones, the blood supply of which can be blocked by UAE. In general, hormones cannot enter UF tissues along with blood flow, and once their receptors are destructed, UFs are bound to further shrink due to the resulting local environment alike that of menopause.<xref rid="ref22" ref-type="bibr">22</xref> Regardless, there remains controversy over the influence of UAE on menstruation and ovarian functions, for which FSH that promotes follicular development is often used as a reliable index for determining ovarian failure.<xref rid="ref23" ref-type="bibr">23</xref> The FSH levels of both groups did not differ significantly before and after intervention, and there were also no significant inter-group differences, indicating that PVA particles were safe for the patients.</p><p>Furthermore, declined quality of life not only weakens physical function, but also negatively affects social, emotional and mental functions.<xref rid="ref24" ref-type="bibr">24</xref> To this end, PVA particles are especially suitable for improving the quality of life because fibrous tissues are able to quickly grow into these evenly diametered particles. Notably, large-sized PVA particles may, instead of entirely occupying the vascular lumen, block blood vessels by triggering thrombosis and thus make vascular recanalization possible owing to embolus dislocation.<xref rid="ref25" ref-type="bibr">25</xref> The two groups scored similarly in physical function, role-physical, bodily pain and general health status before intervention, but the treatment group had significantly higher scores than the control group did six months after intervention (P&#x0003c;0.05).</p><p>In summary, interventional embolization therapy can well treat UFs while only mildly affecting ovarian function. Small-sized PVA particles can improve the quality of life by shrinking the uterus and UFs as well as by lowering the risks of complications. Given insufficient fund and long-term observation, only small sample size was used in this study. Meanwhile, quantification of decrease in UF volume, rather than evaluation on the degree of embolization, was conducted herein. Furthermore, changes in ovarian sex hormones were not subjected to long-term follow-up.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold><italic>Declaration of interest:</italic></bold> None.</p></fn></fn-group><sec id="sec1-5"><title/><sec id="sec2-11"><title>Authors&#x02019; contributions</title><p><bold>XW and WZ:</bold> Designed this study and wrote this manuscript.</p><p><bold>ZZ and JP:</bold> Performed this study and collected data.</p></sec></sec><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlotnik</surname><given-names>E</given-names></name><name><surname>Lorenzo Messina</surname><given-names>Md</given-names></name><name><surname>Nasser</surname><given-names>F</given-names></name><name><surname>Affonso</surname><given-names>BB</given-names></name><name><surname>Baroni</surname><given-names>RH</given-names></name><name><surname>Wolosker</surname><given-names>N</given-names></name><etal/></person-group><article-title>Predictive factors for pelvic magnetic resonance in response to arterial embolization of a uterine leiomyoma</article-title><source>Clinics (Sao Paulo)</source><year>2014</year><volume>69</volume><issue>3</issue><fpage>185</fpage><lpage>189</lpage><comment>doi: 10.6061/clinics/2014(03)07</comment><pub-id pub-id-type="pmid">24626944</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>YJ</given-names></name><name><surname>Chae</surname><given-names>B</given-names></name><name><surname>Kwak</surname><given-names>SH</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Jo</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro</article-title><source>Int J Med Sci</source><year>2014</year><volume>11</volume><issue>3</issue><fpage>276</fpage><lpage>281</lpage><comment>doi: 10.7150/ijms.7627</comment><pub-id pub-id-type="pmid">24516352</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambat</surname><given-names>S</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>DN</given-names></name><name><surname>Misra</surname><given-names>R</given-names></name><name><surname>Dadhwal</surname><given-names>V</given-names></name><name><surname>Ghosh</surname><given-names>B</given-names></name></person-group><article-title>Uterine artery embolization versus laparoscopic occlusion of uterine vessels for management of symptomatic uterine fibroids</article-title><source>Int J Gynaecol Obstet</source><year>2009</year><volume>105</volume><issue>2</issue><fpage>162</fpage><lpage>165</lpage><comment>doi: 10.1016/j.ijgo.2009.01.006</comment><pub-id pub-id-type="pmid">19232612</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>IJ</given-names></name><name><surname>Park</surname><given-names>SI</given-names></name><name><surname>Won</surname><given-names>JY</given-names></name><etal/></person-group><article-title>The effect of uterine artery embolization on premenstrual symptoms in patients with symptomatic fibroids or adenomyosis</article-title><source>J Vasc Interv Radiol</source><year>2014</year><volume>25</volume><issue>6</issue><fpage>833</fpage><lpage>838.e1</lpage><comment>doi: 10.1016/j.jvir.2014.01.036</comment><pub-id pub-id-type="pmid">24657088</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>R</given-names></name><name><surname>Kachura</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Shapiro</surname><given-names>H</given-names></name></person-group><article-title>Laparoscopic myomectomy versus uterine artery embolization: long-term impact on markers of ovarian reserve</article-title><source>J Obstet Gynaecol Can</source><year>2014</year><volume>36</volume><issue>3</issue><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">24612893</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsumori</surname><given-names>T</given-names></name><name><surname>Akazawa</surname><given-names>K</given-names></name><name><surname>Mihara</surname><given-names>T</given-names></name></person-group><article-title>Uterine artery embolization for pedunculated subserosal fibroids</article-title><source>AJR Am J Roentgenol</source><year>2014</year><volume>184</volume><issue>2</issue><fpage>399</fpage><lpage>402</lpage><comment>doi: 10.2214/ajr.184.2.01840399</comment><pub-id pub-id-type="pmid">15671352</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>MQ</given-names></name><name><surname>Suo</surname><given-names>ST</given-names></name><name><surname>Zhang</surname><given-names>XB</given-names></name><name><surname>Zhong</surname><given-names>YC</given-names></name><name><surname>Zhuang</surname><given-names>ZG</given-names></name><name><surname>Cheng</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Entropy of T2-weighted imaging combined with apparent diffusion coefficient in prediction of uterine leiomyoma volume response after uterine artery embolization</article-title><source>Acad Radiol</source><year>2014</year><volume>21</volume><issue>4</issue><fpage>437</fpage><lpage>444</lpage><comment>doi: 10.1016/j.acra.2013.12.007</comment><pub-id pub-id-type="pmid">24594413</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szamatowicz</surname><given-names>M</given-names></name><name><surname>Kotarski</surname><given-names>J</given-names></name></person-group><article-title>Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women</article-title><source>Ginekol Pol</source><year>2013</year><volume>84</volume><issue>3</issue><fpage>219</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">23700851</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLucas</surname><given-names>B</given-names></name><name><surname>Danzer</surname><given-names>H</given-names></name><name><surname>Wambach</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name></person-group><article-title>Ovarian reserve following uterine artery embolization in women of reproductive age: a preliminary report</article-title><source>Minim Invasive Ther Allied Technol</source><year>2013</year><volume>22</volume><issue>1</issue><fpage>45</fpage><lpage>49</lpage><comment>doi: 10.3109/13645706.2012.743918</comment><pub-id pub-id-type="pmid">23311507</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>W</given-names></name><name><surname>Yogo</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>H</given-names></name><name><surname>Ozaki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment</article-title><source>Theranostics</source><year>2013</year><volume>3</volume><issue>6</issue><fpage>366</fpage><lpage>376</lpage><comment>doi: 10.7150/thno.5860</comment><pub-id pub-id-type="pmid">23781284</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marret</surname><given-names>H</given-names></name><name><surname>Fritel</surname><given-names>X</given-names></name><name><surname>Ouldamer</surname><given-names>L</given-names></name><name><surname>Bendifallah</surname><given-names>S</given-names></name><name><surname>Brun</surname><given-names>JL</given-names></name><name><surname>De Jesus</surname><given-names>I</given-names></name><etal/></person-group><article-title>Therapeutic management of uterine fibroid tumors: updated French guidelines</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2012</year><volume>165</volume><issue>2</issue><fpage>156</fpage><lpage>164</lpage><comment>doi: 10.1016/j.ejogrb.2012.07.030</comment><pub-id pub-id-type="pmid">22939241</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundquist</surname><given-names>CM</given-names></name><name><surname>Loo</surname><given-names>C</given-names></name><name><surname>Meraz</surname><given-names>IM</given-names></name><name><surname>Cerda</surname><given-names>JD</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Serda</surname><given-names>RE</given-names></name></person-group><article-title>Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines</article-title><source>Med Sci (Basel)</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>51</fpage><lpage>69</lpage><comment>doi: 10.3390/medsci2010051</comment><pub-id pub-id-type="pmid">24932409</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-L&#x000f3;pez</surname><given-names>FR</given-names></name><name><surname>Ornat</surname><given-names>L</given-names></name><name><surname>Ceausu</surname><given-names>I</given-names></name><name><surname>Depypere</surname><given-names>H</given-names></name><name><surname>Erel</surname><given-names>CT</given-names></name><name><surname>Lambrinoudaki</surname><given-names>I</given-names></name><etal/></person-group><article-title>EMAS position statement: Management of uterine fibroids</article-title><source>Maturitas</source><year>2014</year><volume>79</volume><issue>1</issue><fpage>106</fpage><lpage>116</lpage><comment>doi: 10.1016/j.maturitas.2014.06.002</comment><pub-id pub-id-type="pmid">24975954</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Iodinated oil-loaded, fluorescent mesoporous silica-coated iron oxide nanoparticles for magnetic resonance imaging/computed tomography/fluorescence trimodal imaging</article-title><source>Int J Nanomedicine</source><year>2014</year><volume>21</volume><issue>9</issue><fpage>2527</fpage><lpage>2538</lpage><comment>doi: 10.2147/IJN.S59754</comment><pub-id pub-id-type="pmid">24904212</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topete</surname><given-names>A</given-names></name><name><surname>Alatorre-Meda</surname><given-names>M</given-names></name><name><surname>Villar-Alvarez</surname><given-names>EM</given-names></name><name><surname>Carregal-Romero</surname><given-names>S</given-names></name><name><surname>Barbosa</surname><given-names>S</given-names></name><name><surname>Parak</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Polymeric-gold nanohybrids for combined imaging and cancer therapy</article-title><source>Adv Healthc Mater</source><year>2014</year><volume>3</volume><issue>8</issue><fpage>1309</fpage><lpage>1325</lpage><comment>doi: 10.1002/adhm.201400023</comment><pub-id pub-id-type="pmid">24764284</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hehenkamp</surname><given-names>WJ</given-names></name><name><surname>Volkers</surname><given-names>NA</given-names></name><name><surname>Birnie</surname><given-names>E</given-names></name><name><surname>Reekers</surname><given-names>JA</given-names></name><name><surname>Ankum</surname><given-names>WM</given-names></name></person-group><article-title>Pain and return to daily activities after uterine artery embolization and hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial</article-title><source>Cardiovasc Intervent Radiol</source><year>2006</year><volume>29</volume><issue>11</issue><fpage>179</fpage><lpage>187</lpage><comment>doi: 10.1007/s00270-005-0195-9</comment><pub-id pub-id-type="pmid">16447002</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><etal/></person-group><article-title>Magnetic resonance imaging-visible and pH-sensitive polymeric micelles for tumor targeted drug delivery</article-title><source>J Biomed Nanotechnol</source><year>2014</year><volume>10</volume><issue>2</issue><fpage>216</fpage><lpage>226</lpage><comment>doi: 10.1166/jbn.2014.1729</comment><pub-id pub-id-type="pmid">24738330</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hehenkamp</surname><given-names>WJ</given-names></name><name><surname>Volkers</surname><given-names>NA</given-names></name><name><surname>Birnie</surname><given-names>E</given-names></name><name><surname>Reekers</surname><given-names>JA</given-names></name><name><surname>Ankum</surname><given-names>WM</given-names></name></person-group><article-title>Uterine artery embolisation in the treatment of uterine fibroids: outcomes of randomised trials</article-title><source>Ned Tijdschr Geneeskd</source><year>2008</year><volume>152</volume><issue>12</issue><fpage>663</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">18438059</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>A</given-names></name><name><surname>Petrucco</surname><given-names>OM</given-names></name><name><surname>Makinoda</surname><given-names>S</given-names></name><name><surname>Wikholm</surname><given-names>G</given-names></name><name><surname>Svendsen</surname><given-names>P</given-names></name><name><surname>Br&#x000e4;nnstr&#x000f6;m</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transarterial embolization of the uterine arteries: patient reactions and effects on uterine vasculature</article-title><source>Acta Obstet Gynaecol Scand</source><year>1998</year><volume>77</volume><issue>3</issue><fpage>334</fpage><lpage>340</lpage></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelage</surname><given-names>JP</given-names></name><name><surname>Guaou</surname><given-names>NG</given-names></name><name><surname>Jha</surname><given-names>RC</given-names></name><name><surname>Ascher</surname><given-names>SM</given-names></name><name><surname>Spies</surname><given-names>JB</given-names></name></person-group><article-title>Uterine fibroid tumors: long-term MR imaging outcome after embolization</article-title><source>Radiology</source><year>2004</year><volume>230</volume><issue>3</issue><fpage>803</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">14990844</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spies</surname><given-names>JB</given-names></name><name><surname>Bruno</surname><given-names>J</given-names></name><name><surname>Czeyda-Pommersheim</surname><given-names>F</given-names></name><name><surname>Magee</surname><given-names>ST</given-names></name><name><surname>Ascher</surname><given-names>SA</given-names></name><name><surname>Jha</surname><given-names>RC</given-names></name></person-group><article-title>Long-term outcome of uterine artery embolization of leiomyomata</article-title><source>Obstet Gynecol</source><year>2005</year><volume>106</volume><issue>5</issue><fpage>933</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">16260509</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Barrefelt</surname><given-names>A</given-names></name><name><surname>Asem</surname><given-names>H</given-names></name><name><surname>Abedi-Valugerdi</surname><given-names>M</given-names></name><name><surname>El-Serafi</surname><given-names>I</given-names></name><name><surname>Saghafian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><issue>12</issue><fpage>3885</fpage><lpage>3894</lpage><comment>doi: 10.1016/j.biomaterials.2014.01.041</comment><pub-id pub-id-type="pmid">24495486</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tropeano</surname><given-names>G</given-names></name><name><surname>Di Stasi</surname><given-names>C</given-names></name><name><surname>Litwicka</surname><given-names>K</given-names></name><name><surname>Romano</surname><given-names>D</given-names></name><name><surname>Draisci</surname><given-names>G</given-names></name><name><surname>Mancuso</surname><given-names>S</given-names></name></person-group><article-title>Uterine artery embolization for fibroids does not have adverse effects on ovarian reserve in regularly cycling women younger than 40 years</article-title><source>Fertil Steril</source><year>2014</year><volume>81</volume><issue>4</issue><fpage>1055</fpage><lpage>1061</lpage><comment>doi: 10.1016/j.fertnstert.2003.09.046</comment><pub-id pub-id-type="pmid">15066463</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullivant</surname><given-names>JP</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Willenberg</surname><given-names>BJ</given-names></name><name><surname>Kozissnik</surname><given-names>B</given-names></name><name><surname>Batich</surname><given-names>CD</given-names></name><name><surname>Dobson</surname><given-names>J</given-names></name></person-group><article-title>Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><issue>9</issue><fpage>17501</fpage><lpage>17510</lpage><comment>doi: 10.3390/ijms140917501</comment><pub-id pub-id-type="pmid">24065092</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Jeong</surname><given-names>YY</given-names></name></person-group><article-title>Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancer</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><issue>8</issue><fpage>15910</fpage><lpage>15930</lpage><comment>doi: 10.3390/ijms140815910</comment><pub-id pub-id-type="pmid">23912234</pub-id></element-citation></ref></ref-list></back></article>